Discovering and developing novel drugs for cancer treatment

Terpenoid Therapeutics, Inc. is a privately-held biotechnology company focused on anti-cancer therapeutics. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents. Two projects are in advanced preclinical testing with lead compounds identified in both projects.

Technology

Terpenoid Bisphosphonates

Terpenoid's bisphosphonate project is based on proprietary terpenoid-modified bisphosphonate inhibitors of geranylgeranyl diphosphate synthase (GGDPS), a novel target for which there are currently no approved drugs. Terpenoid predicts that inhibition of GGDPS will result in efficacy in the treatment of primary tumors and metastases (including, but not limited to, bone metastases).

Terpenoid Schweinfurthins

Terpenoid's schweinfurthin project is focused on discovering and developing a drug with activity against primary tumors and metastases. This project is based on rare schweinfurthin natural products whose unique profile of anti-cancer activity was first reported by the National Cancer Institute in 1998

Terpenoid Therapeutics elects Stephen Collins as Chairman

By Terpenoid | May 20, 2013 - 2:48 pm | News

Terpenoid Therapeutics elects Stephen Collins as Chairman. Terpenoid Therapeutics Inc., a University of Iowa spinout company based in Coralville, Iowa, recently elected Stephen Collins, M.D., Ph.D. as Chairman of its Board of Directors. The announcement was made at its annual shareholders meeting, which took place on May 8th, 2013 in … Read more →

Start-ups get feedback at Innovation Expo

By Terpenoid | September 21, 2012 - 10:01 am | News

TTI was recently mentioned in this article in the Cedar Rapids Gazette By Dave DeWitte …Several presenters were established businesses that are looking for funding, resources or ideas to let them grow. Terpenoid Therapeutics’ Raymond Hohl seemed to dazzle his critique panel at the Seed and Venture Forum with his … Read more →

Recasting natural product research

By Terpenoid | June 10, 2012 - 11:36 pm | News

Terpenoid Therapeutics was recently mentioned in this Nature Biotechnology article: By Cormac Sheridan Can the commercial sector capitalize on the merger of high-throughput technology and natural products? Cormac Sheridan investigates. The recent fanfare surrounding Warp Drive Bio, a startup with an ambitious agenda to marry natural products–based drug discovery with … Read more →